⊙记者 李小兵 ○编辑 全泽源

⊙ reporter LiXiaoBing ○ edit all ze source

　　已经许久没有项目上市的红塔创新投资股份有限公司有望重新“开张”。山东元利科技股份有限公司拟IPO，现已接受兴业证券(601377,股吧)的辅导。记者发现，红塔创新投出现在山东元利的股东名单中。此次山东元利仅披露了两名主要发起人股东，一个是公司法人代表刘修华，另一个就是红塔创新投。

Has been a long time did not project listing of hongta innovation investment co., LTD., is expected to"opening".The shandong yuan science and technology co., LTD., quasi IPO,Now accept the securities(601377,guba)counselling.Reporter discovery,Hongta innovation in shandong yuan for the shareholders list.The shandong yuan the only revealed two main promoter shareholders,One is the company legal representative LiuXiuHua,Another is for hongta innovation.

　　资料显示，山东元利创立于2003年，是一家专业从事精细化学品研发与生产的大型民营企业，位于中国精细化工产业基地（昌乐），也是该基地的重点企业。公司主要有三大系列产品：仲辛醇精制及其酯类系列产品、二元酸二甲酯合成及其分离精制系列产品、萃取精馏法焦化粗苯精制系列产品等。

Data shows,The shandong yuan founded in 2003,Is one specialized is engaged in the development and production of fine chemicals of large private enterprises,Is located in China fine chemical industry base(ChangLe),Is also the base of the key enterprises.The company mainly has three series products:Sec-octyl alcohols refined and its esters series products/Dimethyl dibasic acid synthesis and separation refined series products/Extractive distillation method coking crude benzol refining series products, etc.

　　根据当地媒体报道，山东元利在今年2月3日召开了有当地政府14个相关部门参加的股改上市协调会，会议听取了公司董事长刘修华关于公司股改上市情况的汇报，并对当时仍存在的问题进行了讨论研究。报道称，会议的召开，进一步扫清了公司上市面临的障碍。

According to local media reports,The shandong yuan in February 3, held a local government 14 related departments in other listed council,The meeting heard the chairman of the company LiuXiuHua about the company listed on the other report,And at that time still to discuss the problem of the research.Reports say,The meeting held,Further cleared the company listed face obstacles.

　　或许是山东元利的高新技术“牌照”，吸引了红塔创新投的投资。此前，红塔创新投表示，其主投方向为“促进科技成果的商品化、高新技术产业化、利用风险投资机制，对信息产业、电信、生物制药、新型材料等领域具有高科技含量及市场潜力的项目进行股权投资。”但是，昨天山东元利方面拒绝透露红塔创新投投资入股公司的具体时间等信息。不过，红塔创新投曾称，其更多关注成熟期的项目，其2010年投资上市的三个项目：沃森生物(300142,股吧)、先河环保(300137,股吧)、华仁药业(300110,股吧)，都是在上市前夕突击入股。而且，凭借着沃森生物的高回报率，红塔创新投在2010年国内PE的账面回报率排行中位列第二。

Perhaps is the shandong yuan high and new technology"licence",Attracted hongta innovation for investment.after,Hongta innovation cast said,Its main throw direction for"Promote the commercialization of scientific and technological achievements/New and high technology industrialization/Use of the risk investment mechanism,For the information industry/telecom/Biological pharmaceutical/The new materials and other fields with high technology content and market potential of the project equity investment."but,Yesterday, shandong yuan and has refused to reveal hongta innovation for investment in the company's specific time waiting for information.but,Hongta innovation has called for,The more attention to mature stage project,Its 2010 investment of listed three projects:Watson biological(300142,guba)/First environmental protection(300137,guba)/HuaRen pharmaceutical(300110,guba),Are listed in eve assault contribution.and,With Watson biological high rate of return,Hongta innovation cast in 2010 domestic PE book returns finishing second in ranking.